PAVEL BUZADZHI: Open Payments
NPI 1790318426 · TULSA, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$9,123 in 152 payments from 17 companies in 2025. Trend: 2023 $6,978 · 2024 $5,964 · 2025 $9,123
Food & beverage: $4,854Travel & lodging: $4,268
| Company | Payments | Amount |
|---|---|---|
| Abbott Laboratories | 27 | $2,594 |
| ABIOMED | 24 | $2,490 |
| United Therapeutics Corporation | 21 | $1,548 |
| CVRx, Inc. | 11 | $823 |
| Alnylam Pharmaceuticals Inc. | 9 | $497 |
| Merck Sharp & Dohme LLC | 11 | $295 |
| AstraZeneca Pharmaceuticals LP | 9 | $209 |
| PFIZER INC. | 14 | $162 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | 7 | $131 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $114 |
Products named: CARDIOMEMS, Barostim Neo System, AMVUTTRA, Tyvaso, THORATEC HEARTMATE 3 LVAS IMPLANT KIT, WINREVAIR, Remodulin, WAINUA.
Industry payments across OK — which companies pay providers there.
